Labiotech.eu (blog)Oxford Spin-out Moves Gene Therapy For Blindness Into Phase III TrialLabiotech.eu (blog)Nightstar Therapeutics will begin the first Phase III trial for a gene therapy targeting choroideremia, a rare disorder leading to complete blind… Continue reading
Stem cell centers on the rise, claim high efficacy for treatment of knee osteoarthritisEurekAlert (press release)(March 6, 2018)-Even with a lack of peer-reviewed evidence, the number of centers advertising stem cell therapies for osteoarthritis (OA) o… Continue reading
Genetic Engineering & Biotechnology NewsGene-Therapy Trials for Inherited Form of Blindness Could Start in Two YearsGenetic Engineering & Biotechnology NewsScientists in the U.S. say human trials of gene therapy for an inherited form of blindness known… Continue reading
|
Patients Now Have the Option to Undergo Immunotherapy Less Frequently
Curetoday.com The Food and Drug Administration (FDA) has approved a supplemental biologics license application adding a four-week dosing schedule for Opdivo (nivolumab) across several of the PD-1 inhibitor’s indications. PUBLISHED March 06, 2018. The Food and Drug … |
|
Rich Pharmaceuticals’ Study Drug RP-323 (TPA) Elevates White Blood Cells (WBCs) Which Play a Vital Role Fighting …
GlobeNewswire (press release) BEVERLY HILLS, CA, March 06, 2018 (GLOBE NEWSWIRE) — Rich Pharmaceuticals, Inc. (OTC: RCHA), is a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology using its study drug RP-323 (TPA). Multiple clinical … |